#Gilead Sciences

As a person living with HIV, I speak out for prevention—sometimes on the evening news!

The approval is based on a small study of 15- to 17-year-olds.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

These interventions are part of the Southern AIDS Coalition’s COMPASS partnerships.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

Venita Ray will manage the group’s role in the $100 million COMPASS initiative.

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

Pre-exposure prophylaxis has an uncertain future among youth under 25.

A report from the O’Neill Institute looks at the numbers and assesses our prevention response. Just in time for AIDSWatch.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.

Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.